Patents by Inventor Jingchuan Zhang
Jingchuan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965420Abstract: Disclosed are a shield tunnel segment structure and a construction method thereof. The shield tunnel segment structure includes segment blocks sequentially spliced in a circumferential direction. Each segment block forms a closed annular segment structure, and outer diameters of adjacent annular segment structures gradually increase in an axial direction. At least two adjacent segment blocks of the same annular segment structure form an annular inner groove, and at least one segment block of the adjacent annular segment structures is provided with an inner bump which matches the annular inner groove. At least two adjacent segment blocks of the same annular segment structure form an annular outer groove, and at least one segment block of the adjacent annular segment structures is provided with an outer bump which matches the annular outer groove. The annular outer grooves and the annular inner grooves are staggered in the circumferential direction.Type: GrantFiled: July 5, 2023Date of Patent: April 23, 2024Assignees: Shandong University, Northeast Electric Power UniversityInventors: Ke Wu, Tao Yang, Yang Zheng, Guodong Li, Zhihao Xing, Hongna Yang, Jiaxiang Xu, Rong Chen, Dongxue Hao, Jizheng Sun, Jingchuan Duan, Hongwei Zhang
-
Patent number: 11944627Abstract: The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.Type: GrantFiled: March 22, 2018Date of Patent: April 2, 2024Assignee: KURA ONCOLOGY, INC.Inventors: Francis Burrows, Linda V. Kessler, Liansheng Li, Pingda Ren, Yi Wang, Tao Wu, Jingchuan Zhang
-
Publication number: 20230026872Abstract: The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.Type: ApplicationFiled: March 22, 2018Publication date: January 26, 2023Inventors: Francis BURROWS, Linda V. KESSLER, Liansheng LI, Pingda REN, Yi WANG, Tao WU, Jingchuan ZHANG, I
-
Patent number: 9221915Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: October 26, 2011Date of Patent: December 29, 2015Assignees: Pfizer Inc., Amgen Fremont Inc.Inventors: Shelley Sims Belouski, Sirid-Aimée Kellerman, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Publication number: 20120052074Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: ApplicationFiled: October 26, 2011Publication date: March 1, 2012Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Shelley Sims Belouski, Sirid-Aimée Kellerman, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Patent number: 8080646Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: March 12, 2009Date of Patent: December 20, 2011Assignees: Amgen Fremont, Inc., Pfizer Inc.Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelly Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Publication number: 20100197005Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: ApplicationFiled: March 12, 2009Publication date: August 5, 2010Applicants: Amgen Fremont Inc., Pfizer Inc.Inventors: Shelley Sims Belouski, Sirid-Aimee Kellermann, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Patent number: 7537762Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: September 6, 2006Date of Patent: May 26, 2009Assignees: Amgen Fremont, Inc., Pfizer Inc.Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelley Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Publication number: 20070065444Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: ApplicationFiled: September 6, 2006Publication date: March 22, 2007Applicants: Amgen Fremont Inc., Pfizer Inc.Inventors: Michael North, Karin Amundson, Vahe Bedian, Shelley Belouski, Dana Hu-Lowe, Xin Jiang, Shannon Karlicek, Sirid Kellermann, James Thomson, Jianying Wang, Grant Wickman, Jingchuan Zhang